Advances in targeted therapies for metastatic colorectal cancer

about

Advances in targeted therapies for metastatic colorectal cancer

Item

http://www.wikidata.org/entity/Q58614752

description

im Mai 2009 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в травні 2009

@uk

name

Advances in targeted therapies for metastatic colorectal cancer

@en

Advances in targeted therapies for metastatic colorectal cancer

@nl

type

Item

label

Advances in targeted therapies for metastatic colorectal cancer

@en

Advances in targeted therapies for metastatic colorectal cancer

@nl

prefLabel

Advances in targeted therapies for metastatic colorectal cancer

@en

Advances in targeted therapies for metastatic colorectal cancer

@nl

P1476

Advances in targeted therapies for metastatic colorectal cancer

@en

P2093

Elena Elez

http://www.w3.org/2001/XMLSchema#string

Francisco Javier Ramos

http://www.w3.org/2001/XMLSchema#string

Jaume Capdevila

http://www.w3.org/2001/XMLSchema#string

Jose Perez-Garcia

http://www.w3.org/2001/XMLSchema#string

Manuel Ruiz-Echarri

http://www.w3.org/2001/XMLSchema#string

Teresa Macarulla

http://www.w3.org/2001/XMLSchema#string

P2860

The receptor for the cytotoxic ligand TRAIL

Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer

The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Cetuximab for the treatment of colorectal cancer.

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

P304

321-333

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/THY.09.11

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Josep Tabernero

P577

2009-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P921

colorectal cancer